NCT07130916 - A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

August 9, 2025

Study Completion Date

December 31, 2027

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Aumolertinib

In Part A, participants will receive aumolertinib 110 mg (2 × 55 mg tablet) once daily, orally administrated under fasted condition (fasting from 2 hours before to 1 hour after dosing) in 21-day treatment cycles. In Part B, participants may continue study intervention (aumolertinib 110 mg once daily) until PD, death, intolerable toxicity, Investigator's decision, lost of follow-up, receiving another anti-cancer therapy, or any other pre-defined discontinuation criteria.

Trial Locations (6)

71000

RECRUITING

Clinical Center University of Sarajevo, Bolnicka 25, Sarajevo

72000

RECRUITING

Cantonal Hospital Zenica, Crkvice 67, Zenica

78000

RECRUITING

Republika Srpska University Clinical Centre of the Republic of Srpska, Dvanaest beba bb, Banja Luka

RECRUITING

University Clinical Hospital Mosta, Bijeli Brijeg bb, Mostar

104 1404

RECRUITING

"MHAT Sveta Sofia Departmet of Medical Oncology Bulgaria Blvd", Sofia

MD-2025

RECRUITING

Arensia Exploratory Medicine Moldova - IMSP Institutul Oncologic. Strada Nicolae Testemitanu Nr 30, Chisinau